Prostate Cancer Clinical Trials in St Louis, Missouri

27 studies are recruiting for prostate cancer in St Louis, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Washington University, School of Medicine, St Louis, Missouri

   Locations

   90 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

2. Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer

   This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Washington University in St. Louis, St Louis, Missouri

   Locations

   8 in total

   Run by

   Varian, a Siemens Healthineers Company

   See if you can join NCT05804318 on ClinicalTrials.gov

3. A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

   AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be re…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Locations

   7 in total

   Run by

   Angiex, Inc.

   See if you can join NCT06440005 on ClinicalTrials.gov

4. Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

   The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Washington University, St Louis, Missouri

   Locations

   6 in total

   Run by

   Blue Earth Diagnostics

   See if you can join NCT07569926 on ClinicalTrials.gov

5. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University School of Medicine in St. Louis, St Louis, Missouri

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

6. Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

   This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Locations

   6 in total

   Run by

   Janux Therapeutics

   See if you can join NCT07545811 on ClinicalTrials.gov

7. Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

   The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of stand…

   Stage

   Phase 3

   Ages

   18 to 100

   Site

   Wash U School of Medicine, St Louis, Missouri

   Locations

   95 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06855277 on ClinicalTrials.gov

8. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

   The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University, St Louis, Missouri

   Locations

   57 in total

   Run by

   Amgen

   See if you can join NCT04221542 on ClinicalTrials.gov

9. A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

   This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Siteman Cancer Center, St Louis, Missouri

   Locations

   19 in total

   Run by

   Pathos AI, Inc.

   See if you can join NCT06785636 on ClinicalTrials.gov

10. Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System

    - The investigators propose a clinical trial to evaluate the impact of annual shared decision making for PSA screening, supported by system-level enhancements to promote evidence-based care: * Defined referral thresholds within the health maintenance reminder, aligned with clinical risk stratificat…

    Stage

    Not phased

    Ages

    40 to 75

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT07109427 on ClinicalTrials.gov

11. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Locations

    33 in total

    Run by

    Parabilis Medicines, Inc.

    See if you can join NCT05919264 on ClinicalTrials.gov

12. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

    Stage

    Phase 1

    Ages

    18 to 100

    Site

    Washington University School of Medicine, St Louis, Missouri

    Locations

    36 in total

    Run by

    Janux Therapeutics

    See if you can join NCT05519449 on ClinicalTrials.gov

13. A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

    ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, St Louis, Missouri

    Locations

    18 in total

    Run by

    AstraZeneca

    See if you can join NCT07336446 on ClinicalTrials.gov

14. IDOV-Immune for Advanced Solid Tumors

    This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potent…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Locations

    5 in total

    Run by

    ViroMissile, Inc.

    See if you can join NCT06910657 on ClinicalTrials.gov

15. Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

    The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant setting followed by radical prostatectomy, and to evaluate the feasibility a…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University, St Louis, Missouri

    Locations

    9 in total

    Run by

    Amgen

    See if you can join NCT06613100 on ClinicalTrials.gov

16. Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients w…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Investigative Site #110, St Louis, Missouri

    Locations

    18 in total

    Run by

    MOMA Therapeutics

    See if you can join NCT06545942 on ClinicalTrials.gov

17. PSMA PET Combined With MRI for the Detection of PCa

    This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Washington University, St Louis, Missouri

    Locations

    18 in total

    Run by

    Telix Pharmaceuticals (Innovations) Pty Limited

    See if you can join NCT07052214 on ClinicalTrials.gov

18. Low-Count Quantitative SPECT for Men Treated With Radium-223

    Internal radiotherapies (radiolabeled molecules that are systemically administered and localize to sites of disease) provide cancer-ablating doses to diseased cells while sparing adjacent normal tissues. [223Ra]RaCl2 (Xofigo) is the first FDA-approved alpha-particle emitting radiopharmaceutical the…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT07221825 on ClinicalTrials.gov

19. Diffusion Basis Spectrum Imaging of the Prostate

    Diffusion Basis Spectrum Imaging (DBSI) represents a potential leap forward in improving prostate cancer early detection: a non-invasive and accurate imaging test for clinically significant prostate cancer.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT04420702 on ClinicalTrials.gov

20. CARE Tool Study Aim 3

    This study is a multi-site randomized trial to study the implementation of the CARE Tool and evaluate the CARE Tool. The CARE Tool is a web-based tool that gives people information about cancer care costs, health insurance, and resources to help with costs. Overall, the study aims to help patients …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Locations

    3 in total

    Run by

    Washington University School of Medicine

    See if you can join NCT07296887 on ClinicalTrials.gov

21. Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

    The purpose of this study is to see what effects, good and/or bad, proton radiation, and/or conventional radiation and hormonal therapy (if applicable), has on prostate cancer that has already returned or the risk of prostate cancer returning.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mercy David C. Pratt Cancer Center, St Louis, Missouri

    Locations

    6 in total

    Run by

    Proton Collaborative Group

    See if you can join NCT00969111 on ClinicalTrials.gov

22. Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

    This phase II trial studies how well atezolizumab works alone or in combination with etrumadenant or tocilizumab in treating men with localized prostate cancer before radical prostatectomy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Alvin J. Siteman Cancer Center at Washington University, St Louis, Missouri

    Locations

    2 in total

    Run by

    David Oh

    See if you can join NCT03821246 on ClinicalTrials.gov

23. Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

    The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as …

    Stage

    Phase 4

    Ages

    18 to 100

    Site

    Wash U School of Medicine, St Louis, Missouri

    Locations

    54 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT05803941 on ClinicalTrials.gov

24. Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

    This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy. Treatment of interest: the investigational tre…

    Stage

    Phase 2

    Ages

    18 to 100

    Site

    WA Uni School Of Med, St Louis, Missouri

    Locations

    81 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT06780670 on ClinicalTrials.gov

25. Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

    This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual external radiation t…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Locations

    57 in total

    Run by

    Canadian Cancer Trials Group

    See if you can join NCT06235697 on ClinicalTrials.gov